Vor Biopharma Inc.: updates and filings

VORNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$19.19

November 20, 2026Market cap $1.2B

What Ploutos Investor adds for Vor Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 30, 2026 latest annualOct 30, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Nov 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Sep 4, 2026Shelf registration for future offerings
    FormS-3ASR
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 21, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 7, 2026Officer or director change
    Form8-K
  • Jun 12, 2026Shareholder vote
    Form8-K
  • Jun 8, 2026Regulation FD disclosure
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 6, 2026Filing
    FormEFFECT
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 4, 2026Correspondence with the SEC
    FormCORRESP
  • May 1, 2026Letter from the SEC
    FormUPLOAD

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 10, 2020.

The full analysis

What do Vor Biopharma's filings show?

The filings are where every one of Vor Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.